AVTX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -18405.73% compared to Avalo Therapeutics's net margin of -49.65%. Avalo Therapeutics's return on equity of -375.96% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Avalo Therapeutics has a consensus price target of $29.88, signalling upside risk potential of 503.54%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 47.24%. Given that Avalo Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Avalo Therapeutics is more attractive than NovaBay Pharmaceuticals.

Avalo Therapeutics has a beta of 0.696, which suggesting that the stock is 30.449% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

Avalo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avalo Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Avalo Therapeutics quarterly revenues are $192K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Avalo Therapeutics's net income of -$13.1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Avalo Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avalo Therapeutics is 1.30x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -18405.73% compared to Avalo Therapeutics's net margin of --. Avalo Therapeutics's return on equity of -375.96% beat Oragenics's return on equity of --.

Avalo Therapeutics has a consensus price target of $29.88, signalling upside risk potential of 503.54%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 731.11%. Given that Oragenics has higher upside potential than Avalo Therapeutics, analysts believe Oragenics is more attractive than Avalo Therapeutics.

Avalo Therapeutics has a beta of 0.696, which suggesting that the stock is 30.449% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.

Avalo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avalo Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Avalo Therapeutics quarterly revenues are $192K, which are larger than Oragenics quarterly revenues of --. Avalo Therapeutics's net income of -$13.1M is lower than Oragenics's net income of -$2.2M. Notably, Avalo Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avalo Therapeutics is 1.30x versus 1.16x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -18405.73% compared to Avalo Therapeutics's net margin of --. Avalo Therapeutics's return on equity of -375.96% beat Theriva Biologics's return on equity of --.

Avalo Therapeutics has a consensus price target of $29.88, signalling upside risk potential of 503.54%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1519.25%. Given that Theriva Biologics has higher upside potential than Avalo Therapeutics, analysts believe Theriva Biologics is more attractive than Avalo Therapeutics.

Avalo Therapeutics has a beta of 0.696, which suggesting that the stock is 30.449% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

Avalo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avalo Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Avalo Therapeutics quarterly revenues are $192K, which are larger than Theriva Biologics quarterly revenues of --. Avalo Therapeutics's net income of -$13.1M is lower than Theriva Biologics's net income of -$4.3M. Notably, Avalo Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avalo Therapeutics is 1.30x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Trevi Therapeutics has a net margin of -18405.73% compared to Avalo Therapeutics's net margin of --. Avalo Therapeutics's return on equity of -375.96% beat Trevi Therapeutics's return on equity of --.

Avalo Therapeutics has a consensus price target of $29.88, signalling upside risk potential of 503.54%. On the other hand Trevi Therapeutics has an analysts' consensus of $21.22 which suggests that it could grow by 256.08%. Given that Avalo Therapeutics has higher upside potential than Trevi Therapeutics, analysts believe Avalo Therapeutics is more attractive than Trevi Therapeutics.

Avalo Therapeutics has a beta of 0.696, which suggesting that the stock is 30.449% less volatile than S&P 500. In comparison Trevi Therapeutics has a beta of 0.591, suggesting its less volatile than the S&P 500 by 40.892%.

Avalo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevi Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avalo Therapeutics pays -- of its earnings as a dividend. Trevi Therapeutics pays out -- of its earnings as a dividend.

Avalo Therapeutics quarterly revenues are $192K, which are larger than Trevi Therapeutics quarterly revenues of --. Avalo Therapeutics's net income of -$13.1M is lower than Trevi Therapeutics's net income of -$10.3M. Notably, Avalo Therapeutics's price-to-earnings ratio is -- while Trevi Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avalo Therapeutics is 1.30x versus -- for Trevi Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.